From Phase 1b:
“We are extremely excited about the data generated from only 4 weeks of treatment. The large reduction in inflammatory acne lesions observed after this short treatment period, is better than the leading topically applied products currently available on the market. We expect to see even greater reductions in acne lesions and continued safety when treatment with BTX 1503 is extended out to 12 weeks.”
Fills me with a lot of confidence.
- Forums
- ASX - By Stock
- BOT
- Ann: Trading Halt
Ann: Trading Halt, page-108
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
32.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $581.5M |
Open | High | Low | Value | Volume |
32.5¢ | 33.0¢ | 32.0¢ | $545.3K | 1.678M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
23 | 705307 | 32.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
33.0¢ | 477282 | 23 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
23 | 774843 | 0.320 |
24 | 845642 | 0.315 |
36 | 1045112 | 0.310 |
14 | 386033 | 0.305 |
31 | 479927 | 0.300 |
Price($) | Vol. | No. |
---|---|---|
0.330 | 434526 | 22 |
0.335 | 209326 | 9 |
0.340 | 394718 | 9 |
0.345 | 436668 | 8 |
0.350 | 178142 | 4 |
Last trade - 14.39pm 13/11/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online